The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline which establishes recommendations for EGFR and ALK testing, helping to guide targeted therapies.
The GUIDELINE was released on April 3, 2013, in Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, and The Journal of Molecular Diagnostics.
The guideline provides answers to these important clinical questions:
- When should testing be performed?
- How should EGFR testing be performed?
- How should ALK testing be performed?
- Should other genes be routinely tested in lung cancer?
- How should molecular testing of lung cancer be implemented?
The implementation of the CAP/IASLC/AMP guideline will ensure a uniform approach to the molecular testing of lung cancer and will improve the effectiveness of lung cancer treatment for patients.
Descarregar guideline aqui
1 – Arch Pathol Lab Med. 2013;137:828–860; doi: 10.5858/ arpa.2012-0720-OA
2 – http://www.cap.org/web/home/resources/cap-guidelines/current-cap-guidelines/molecular-testing-guideline-lung-cancer-patients?_afrLoop=487896998161711#!%40%40%3F_afrLoop%3D487896998161711%26_adf.ctrl-state%3D11qsijoptl_95